Bioequivalence Study of GP-IMP-001 in Comparison to Reference Product in Healthy Volunteers

The primary objective of this study is to evaluate the **bioequivalence** of GP-IMP-001 in comparison to a reference product. This assessment is conducted in **healthy volunteers** to ensure that GP-IMP-001 has similar pharmacokinetic properties to the reference, which is crucial for confirming its therapeutic equivalence and safety profile. The study does not list any secondary objectives.

The clinical trial involves **healthy volunteers** as the study population, specifically focusing on male participants. The age range of the participants is categorized under code "3," which typically corresponds to a specific adult age group, although the exact ages are not specified. The total number of participants is not provided, as the sponsor did not give this information. The trial population was selected to exclude vulnerable populations, ensuring a focus on individuals without significant health issues. Lifestyle considerations such as diet, physical activity, or habits are not detailed in the available data. The selection criteria for participation, including any key inclusion or exclusion criteria, are not specified in the provided information.

The clinical trial is designed to evaluate the **bioequivalence** of GP-IMP-001 in comparison to a reference product. This study will be conducted with **healthy volunteers** and is categorized as a Phase 2 trial. The trial will employ a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated recruitment start date is January 10, 2025, with the trial expected to conclude by February 28, 2025. Participants will be involved in the study for a duration that aligns with the trial's timeline, from recruitment to the end-of-study visit.

The sequence of study visits will begin with an inclusion (screening) visit, where potential participants will be assessed for eligibility based on predefined criteria. Following successful screening, participants will be randomized and will undergo a series of follow-up visits. These visits are designed to monitor the participants' health status, adherence to the study protocol, and any adverse events. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to gather comprehensive data on the study's outcomes.

Participants are expected to remain in the study for its entire duration unless specific conditions necessitate early termination. Such conditions may include the occurrence of significant adverse events, non-compliance with the study protocol, or withdrawal of consent by the participant. The study's design and procedures are structured to ensure the safety and well-being of participants while achieving the trial's scientific objectives.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on January 10, 2025, with an estimated completion date of February 28, 2025. The efficacy assessment will be conducted using predefined primary and secondary endpoints, although specific endpoints are not detailed in the provided data. The trial will follow a structured methodology to ensure accurate and reliable measurement of efficacy parameters. Data collection and analysis will be performed at designated timepoints throughout the trial duration, adhering to standard clinical trial protocols. The trial's focus on efficacy evaluation will contribute to understanding the therapeutic potential of the investigational product within the specified timeframe.